Dementia clinical trials

Explore recruiting dementia clinical trials.

Recruiting dementia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dementia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2a multi-site, randomized, double-blind, dose escalated, placebo-controlled biomarker study to determine the safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in subjects with MCI (Mild Cognitive Impairment) or mild dementia due to Alzheimer’s disease (AD) aged 50 to 85 years

Denmark, Iceland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Placebo-Controlled, Double-Blind Study of XPro™ in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation

Poland, France, Spain, Germany, Czechia, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

Germany, Netherlands, Finland, France, Italy, Norway +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

Iceland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)

France, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Dementia trials by city

Dementia in Toronto Dementia in Vancouver Dementia in Montreal Dementia in Calgary Dementia in Edmonton Dementia in Ottawa Dementia in Winnipeg Dementia in Quebec City Dementia in Hamilton Dementia in Kitchener Dementia in London Dementia in Halifax Dementia in New York Dementia in Los Angeles Dementia in Chicago Dementia in Houston

Other conditions

IgA nephropathy Polycystic kidney disease Migraine Alzheimer's disease Parkinson's disease Multiple sclerosis Epilepsy ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Depression Anxiety Bipolar disorder Schizophrenia PTSD OCD ADHD Insomnia Postpartum depression Alcohol use disorder Substance use disorder COPD